Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L

J Clin Oncol, (7):1138-1144 2010

MED: 20124182

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J

J Clin Oncol, (14):1594-1600 2012

MED: 22393084

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P

Lancet Oncol, (1):25-32 2011

MED: 22153890

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team, Lerzo G, Fein L, Varela M, Zarba J, Blajman C, Piccart M, Wildiers H, Vuylsteke P, Nouwynck C, Pinczowski H, Vinholes JJ, Oliveira C, Roy JA, Palacova M, Donocikova B, Bendova M, Domont J, Petit T, Cure H, Achille M, Eidtmann H, Keil E, Tome O, Kuemmel S, Hackmann J, Kunz G, Kloepper E, Reimer T, Thomssen C, Schwedler K, Ng WM, Kwong A, Chow L, Lang I, Dasappa L, Chopra R, Mehta A, Gupta S, Ferro A, Visini M, Del Mastro L, Colleoni M, Miglietta L, Bidoli P, Kim SB, Sohn JH, Im YH, Ciceniene A, Naume B, Wist E, Gomez H, de Mendoza FH, Eniu A, Gorbunova V, Semiglazov V, Shomova M, Manikhas A, Coccia-Portugal M, Pirjol A, Dreosti L, Moodley S, Baselga J, Ciruelos E, Di Cosimo S, Llombart A, Mora MA, Pena JC, Borrego MR, Martin AG, Lopez R, Holmberg S, Tseng LM, Chang TW, Huang CS, Hsieh RK, Chen DR, Hickish T, Patel A, Chan S, Roylance R

Lancet, (9816):633-640 2012

MED: 22257673

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, [...] Conte P

J Clin Oncol, (16):1989-1995 2012

MED: 22493419

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41

Robidoux

J Clin Oncol, (18 Suppl) 2012

Cardiac dysfunction in the trastuzumab clinical trials experience.

Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D

J Clin Oncol, (5):1215-1221 2002

MED: 11870163

Adjuvant trastuzumab in HER2-positive breast cancer.

N Engl J Med, (14):1273-1283 2011

MED: 21991949

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.

Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, [...] Wolmark N

J Clin Oncol, (31):3792-3799 2012

MED: 22987084

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group, Bartoli MA, Bianconi MI, Kotliar M, Lacava JA, Matwiejuk M, Price PE, Varela M, Andrade J, Araujo R, Azevedo S, Cortes E, Costa e Silva E, Cubero D, Delgado G, Diz Mdel P, Eyll B, Franke F, Hegg R, Ismael G, Jendiroba D, Pedrini JL, Pereira R, Pinczowski H, Tokunaga P, Tosello C, Brezden-Masley C, Cheng Y, Ouyang X, Shen Z, Wang X, Wang L, Yau TK, Yeo W, Otero D, Soldic Z, Vrbanec D, Soria T, Kellokumpu-Lehtinen P, Pyrhonen S, Campone M, Coudert B, Ferrero JM, Priou F, Aktas B, Aulitzky W, Clemens M, Grischke EM, Hauschild M, Just M, Kirsch A, Kuemmel S, Maintz C, Marme A, Mueller V, Schmidt M, Schneeweiss A, Schumacher C, Thomssen C, Wesenberg B, Castro-Salguero H, Hernandez Monroy C, Zelina-Toache LM, Amadori D, Angiolini C, Biganzoli L, Cinieri S, Gamucci T, Iacobelli S, Latini L, Montemurro F, Simoncini E, Aogi K, Fuji H, Horiguchi J, Inoue K, Ito Y, Iwata H, Kashiwaba M, Kohno N, Kuroi K, Masuda N, Nakagami K, Nakayama T, Nishimura R, Saji S, Sasaki Y, Sato N, Takeda K, Tokuda Y, Tsugawa K, Ueno T, Watanabe J, Yoshiaki R, Im SA, Im YH, Kim SB, Moon YW, Ro JS, Sohn JH, Grincuka E, Kudaba I, Purkalne G, Kostovska-Maneva L, Stefanovski P, Martinez G, Tellez G, Caguioa P, Chan V, Tudtud D, Foszczynska-Kloda M, Pienkowski T, Polkowski W, Starowslawska E, Tomczak P, Gorbunova V, Gotovkin E, Kiselev I, Kopp M, Lichinitser M, Merkulov V, Roman L, Semiglazov V, Shirinkin V, Lee SC, Wong ZW, Alba Conejo E, Baselga J, Batista N, Calvo L, Ciruelos E, Cortes J, Gil i Gil M, Gonzalez A, Hornedo Muguiro J, Morales S, Ribelles Entrena N, Sanchez Sde L, Sanchez Rovira P, Arpornwirat W, Dejthevaporn T, Maneechavakajorn J, Srimuninnimit V, Sriuranpong V, Sunpaweravong P, Ahmad R, Assersohn L, Boiangiu I, Davidson N, Gallagher C, Jones A, Miles D, O'Reilly S, Robinson A, Wheatley D, Agajanian R, Armor JF, Audeh MW, Behairy AS, Birhiray R, Blachly R, Blackwell K, Blanchard R, Blanchet P, Bowers BJ, Brufsky A, Budde L, Carroll RR, Charu V, Dakhil S, Daniel B, Ellerton JA, Fehrenbacher L, Flynn P, Franco S, Green N, Hansen V, Hargis J, Hendricks C, Hermann RC, Kallab A, Karwal M, Kato G, Kaufman P, Kennedy PS, Klein P, Lester EP, Lobo CF, Michaelson RA, Neidhart JA, Neidhart JD, Nguyen AD, O'Rourke T, Patel R, Patel T, Perez A, Quackenbush JA, Peterson CE, Polikoff JD, Prill SJ, Robles R, Rodriguez G, Senecal F, Sharma P, Smith R, Spicer D, Swain SA, Taguchi JA, Vogel CL, Waterhouse DM, Yadav S, Yardley DA

N Engl J Med, (2):109-119 2011

MED: 22149875